Bursa Malaysia (KLSE) Stock Investment Portal

DUBAI: Bahrain said on Friday it has granted emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, becoming the second country after Britain to approve it.

The kingdom had also approved Sinopharm’s COVID-19 vaccine in November for use by frontline workers.

https://www.arabnews.com/node/1772516/middle-east

Stock

Stock: [ZENTECH]: ZEN TECH INTERNATIONAL BERHAD

2020-12-05 01:36 | Report Abuse

Stock

Stock: [DKSH]: DKSH HOLDINGS(M)BHD

2020-12-05 01:36 | Report Abuse

Stock

Stock: [NEXGRAM]: NEXGRAM HOLDINGS BERHAD

2020-12-05 01:35 | Report Abuse

Stock

Stock: [MTRONIC]: METRONIC GLOBAL BHD

2020-12-05 01:34 | Report Abuse

Stock

Stock: [MTOUCHE]: MTOUCHE TECHNOLOGY BHD

2020-12-05 01:34 | Report Abuse

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:34 | Report Abuse

Just a gut feeling next week may be uptrend....

Stock

Stock: [MQTECH]: MQ TECHNOLOGY BHD

2020-12-05 01:33 | Report Abuse

Stock

Stock: [AHEALTH]: APEX HEALTHCARE BHD

2020-12-05 01:33 | Report Abuse

Stock

Stock: [TNLOGIS]: TIONG NAM LOGISTICS HOLDINGS

2020-12-05 01:32 | Report Abuse

Stock

Stock: [TASCO]: TASCO BERHAD

2020-12-05 01:30 | Report Abuse

Stock

Stock: [KGB]: KELINGTON GROUP BERHAD

2020-12-05 01:30 | Report Abuse

Stock

Stock: [SOLUTN]: SOLUTION GROUP BERHAD

2020-12-05 01:29 | Report Abuse

Stock

Stock: [HWGB]: HO WAH GENTING BHD

2020-12-05 01:29 | Report Abuse

Stock

Stock: [BINTAI]: BINTAI KINDEN CORPORATION BHD

2020-12-05 01:29 | Report Abuse

Stock

Stock: [DPHARMA]: DUOPHARMA BIOTECH BERHAD

2020-12-05 01:28 | Report Abuse

Stock

Stock: [PHARMA]: PHARMANIAGA BHD

2020-12-05 01:27 | Report Abuse

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:26 | Report Abuse

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:21 | Report Abuse

Looks like the executive director Steven Kuah is the one calling the shots, not Mr Wu Wai Kong. Thank god....I would be quite worried if it was Mr Wu calling the shots...

---------------

Kanger boosted by Malaysia in China's "priority vaccine recipient" list

KUALA LUMPUR: Kanger International Bhd aims to build its business with Chinese firms involved in the medical field and bamboo processing, says its executive director Steven Kuah.

Kuah told the New Straits Times top in the list was to distribute the Covid-19 vaccine in Malaysia soon, and regionally from early next year.

Kuah said the company planned to use part of the proceed for its healthcare venture.

"This is a long term plan for Kanger to improve its performance," Kuah said.

Kuah said Kanger was set to become the world's largest producer of bamboo products with the commencement of its new bamboo processing plant and R&D centre in China, developed in collaboration with the local government of Jingzhou, Hunan province.

https://www.malaymail.com/news/malaysia/2020/12/04/dr-noor-hisham-malaysia-to-start-final-testing-for-covid-19-vaccine-to-ensu/1928851

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:16 | Report Abuse

I doubt Mr Wu is one of the buyers of the PP.. Doesnt make any sense....

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:12 | Report Abuse

Looks like Malaysia is getting serious about China Vaccines...

-----------
Dr Noor Hisham: Malaysia to start final testing for Covid-19 vaccine to ensure population suitability

PUTRAJAYA, Dec 4 — Malaysia will soon embark on the third phase clinical trial for the one of its Covid-19 vaccine candidates, said Health director-general Tan Sri Dr Noor Hisham Abdullah today.

He said the trial will use the inactivated virus vaccine that was developed by China’s Institute of Medical Biology Chinese Academy of Medical Sciences in Beijing.

“We decided to carry out the trial following the first and second phase clinical trials, which indicated the vaccine is safe and produced good results,” Dr Noor Hisham said during his press conference.

However, he stressed that the main objective of conducting the third-phase clinical trial for the vaccine is to ensure it is suitable for the Malaysian population.

“The study aims to further investigate the vaccine’s safety and efficacy. It may work in populations in other countries, but what about Malaysia?

“The trial has been registered under the National Medical Research Registry, and will be conducted by a principal investigator under the ministry, with assistance from a local clinical research organisation,” Dr Noor Hisham said.

The trial, he said, will be conducted in eight centres under the ministry’s supervision, located in hospitals around the country.

“These include the Ampang Hospital, the Sarawak General Hospital, the Sungai Bulah Hospital in Selangor, the Penang Hospital and the Seberang Jaya Hospital in Penang, the Sultanah Bahiyah Hospital in Kedah and the Raja Permaisuri Bainun Hospital in Klang.

“Hopefully by this coming Thursday (December 10) we will review the trial with the Medical Research and Ethics Committee, to look into the legal and research ethics aspects.

“Once approved, we can probably start the study by the end of this month or next year,” he said, adding that the trial is expected to involve 3,000 participants.

https://www.malaymail.com/news/malaysia/2020/12/04/dr-noor-hisham-malaysia-to-start-final-testing-for-covid-19-vaccine-to-ensu/1928851

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:04 | Report Abuse

@GoUpUp Those shares are probably part of Mr Wu ESOS....

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 01:02 | Report Abuse

Luckily it is not Mr. Wu Wai Kong calling the shots. If it was him, i would be quite suspicious...

“Just recently, the Malaysian and Chinese governments signed an agreement to foster greater collaboration in combating the Covid-19 pandemic, which includes cooperation in vaccine research and development (R&D) and supply,” said Kanger executive director Steven Kuah Choon Ching.

https://www.theedgemarkets.com/article/no-objection-kanger-purchase-covid19-vaccine

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 00:45 | Report Abuse

China set to mass-produce its Covid vaccines
Inspections by Beijing’s expert on Covid point to mass production and inoculations

The latest sign of speeding up the production and immunization drive – a bonanza for Chinese drugmakers – comes from Deputy Premier Sun Chunlan, a member of the Communist Party’s high-powered Politburo and Beijing’s point man on Covid-19 containment.

On Wednesday and Thursday, Sun inspected a cluster of research institutes, pharmaceutical firms, production lines and industry watchdogs in Beijing that have been leading the charge with vaccines.

While visiting the lab of the China National Biotec Group (CNBG), a subsidiary of the state-owned China National Pharmaceutical Group (SINOPHARM), Sun was quoted by Xinhua as saying that she expected a “quick turnaround” from regulators in their approval of those promising vaccine candidates and that drugmakers must now stack ingredients and calibrate their equipment in readiness to start operations once Beijing gives the go-ahead.

She also inspected SinoVac, another frontrunning developer of vaccines.

With public health under her purview, Sun turned the corner of China’s initially botched response to the coronavirus in February. She flew into Wuhan, the original epicenter of the pandemic, and marshaled and commanded a contingent of doctors and equipment to the city and eventually stamped out the pathogen after a 76-day city-wide lockdown.

State media reports now suggest that Sun is again making all the running in regulatory approval, production, distribution and inoculation of Chinese vaccines.

At the National Medical Products Administration, she asked watchdogs to raise the bar and apply “internationally recognized standards and protocols” in their vetting and approval to ensure the vaccines would be up to scratch.

A Xinhua circular about Sun’s speech during her inspection visits also revealed that she had been chairing a State Council panel tasked with drafting a nationwide distribution and triage plan to accord priority for those in urgent need.

A separate Xinhua report noted that initial batches of vaccines would be primed for frontline medical centers and border checkpoints. By the end of the year all medical staff, immigration and customs officers and other essential personnel across the nation would be included in the “emergency but voluntary vaccination program,” with vetted participants reputedly being administered two doses of the vaccine from SINOPHARM.

The state-owned drug-making conglomerate also filed applications with authorities at the end of November for its vaccines to hit the market, with SINOPHARM President Liu Jingzhen reportedly vowing in his report to Sun that once approved, the group could deliver 100 million doses by the year’s end and scale up its turnover to 1 billion by the end of 2021.

China is expected to order in bulk from producers for both mass vaccination at home and donations to a number of countries from Asia to Africa.

On Friday, Xinhua and other state media outlets also quoted National Health Commission officials as saying that 600 million doses – matching half of China’s population – would be ready by the New Year break, though no specific breakdown of supply sources was given in related reports.

Other than an attenuated vaccine from its CNBG arm inspected by the deputy premier, another vaccine candidate of the same type from SINOPHARM’s Wuhan Institute of Bio Products is also making headway in final trials.

An epidemiologist with Shanghai’s Municipal Center for Disease Control and Prevention told Asia Times that SINOPHARM and SinoVac were playing it safe with their vaccines, developed with existing research platforms and manufacturing capacities.

He said such vaccines were based on safe, weakened viruses to simulate a natural infection to trigger an immune response.

“Chinese drugmakers have changed the calculus of their vaccine R&D to try to cram as much as 10 years worth of research work into just eight to 10 months, and that would have not been possible had it not been for the existing groundwork and knowledge we already have about attenuated vaccines, a path that is time-tested and proven to be safe as most of the vaccines we already have against various diseases belong to this category,” said the expert.

https://asiatimes.com/2020/12/china-set-to-mass-produce-its-covid-vaccines/

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-05 00:25 | Report Abuse

China set to roll out its COVID-19 vaccination
Beijing prepares to approve 600m inactivated doses by end-December

SHANGHAI -- China is making the final preparations before rolling out a COVID-19 vaccine for emergency use and mass production, even as clinical trials for various vaccines continue locally and abroad.

Unlike some countries, which have already authorized vaccines, Beijing is treading cautiously, balancing the needs of serving a huge domestic population and meeting international demand, with several vaccine candidates being trialed.

Vice premier Sun Chunlan said on Wednesday that the groundwork for production and emergency use of a vaccine was "progressing smoothly," and she called for people in high-risk workplaces -- such as ports -- to be inoculated this month.

China has had sporadic local infections in recent months which authorities have blamed on imported frozen food packaging.

Sun made her remarks when visiting China's National Institute for Food and Drug Control, an agency that comes under the National Medical Product Administration, the country's drugs regulator.

The visit was seen as a prelude to the commercialization of a COVID-19 vaccine in China, according to the Global Times, a mouthpiece of the Chinese Communist Party. Sun also visited two vaccine producers, Sinovac Biotech and the National Vaccine & Serum Institute, part of state-owned pharma group Sinopharm.

China is set to approve 600 million doses of an inactivated COVID-19 vaccine by the end of this month, Wang Junzhi, a member of the national vaccine research and development specialist group, said at a conference in Wuhan on Friday.

Sinovac and Sinopharm are two Chinese pharmaceutical companies that use inactivated virus as the immunology agent in their vaccine candidates. They join three other Chinese peers in preparing a total of 14 candidates that are undergoing final stage clinical trials internationally.

Under normal conventions, vaccine development is a long and complex process, taking at least 10 years before commercialization.

China's approach is "relatively cautious" due to its huge population, with an attempt to balance all stakeholders in the process, according to an immunologist in Shanghai who did not want to be identified.

Apart from a commitment to market the vaccines when they become available, Chinese companies are conducting clinical trials in more than a dozen countries, as well as at home.

Shanghai Fosun Pharmaceutical is among the latest to trial the mRNA COVID-19 vaccine developed by Germany's BioNTech and Pfizer of the U.S., in a phase 2 clinical trial involving 960 participants in Jiangsu Province, according to an announcement on Nov. 25. Fosun agreed earlier this year to pay up to $135 million towards the vaccine's development and for the right to commercialize it locally. The vaccine has already received approval in the U.K. for emergency use.

Within China, local governments in Jiangsu, Zhejiang and Sichuan provinces have all started vaccine procurement bids from local producers, according to reports.

https://asia.nikkei.com/Spotlight/Coronavirus/China-set-to-roll-out-its-COVID-19-vaccination

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-04 23:03 | Report Abuse

@1212trade Exactly. Mr Wu is the culprit disposing his shares. All those dumb people who falsely accuse me of suppressing the price, i hope god punishes them. Remember Fitnah is worse than killing...

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-04 23:00 | Report Abuse

What we know about China’s coronavirus vaccines

But we may see some data and more widespread use of Chinese vaccines soon. On Friday (Dec. 4), Wang Junzhi, the deputy head of China’s task force on vaccine development, said at a briefing that China has 600 million doses ready to administer this year, and promised a “major announcement in the coming one to two weeks.” Wang’s remark came days after Sun Chunlan, China’s vice premier, gave instructions for Chinese drug makers to be prepared to mass-produce the shots during her visit to a major vaccine maker in Beijing.

The rollout of China’s vaccines, like those out of the US and Europe, will have a major impact not only on the global efforts to stop the pandemic, but also on the international diplomatic landscape as Beijing promises developing countries priority access to its doses.

Two of the vaccines are being developed by the state-run China National Pharmaceutical Group, or Sinopharm, both via its subsidiary China National Biotec Group (CNBG). For one of the vaccines, known by the initials BBIBP-CorV, a Beijing unit of the subsidiary is working with China’s Center for Disease Control, while the other vaccine is being developed by a Wuhan unit.

Sinopharm’s vaccines were the first among the Chinese vaccines to begin widespread human trials, starting in mid-July in the United Arab Emirates. Later that month, Nasdaq-listed Sinovac, which is developing a vaccine called CoronaVac, also began its late-stage trial in São Paulo, Brazil.

When is a mass rollout in China expected?
Perhaps as soon as the end of this year, based on Wang’s comments.

https://qz.com/1940097/what-we-know-about-chinas-covid-19-vaccines/

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-04 22:11 | Report Abuse

Coronavirus: China to have 600 million doses of vaccines ‘ready for use this year’

China will have 600 million doses of Covid-19 vaccines ready for use this year and WILL MAKE “A MAJOR ANNOUNCEMENT” SOON, a scientist in charge of vaccine development in the country said on Friday.

Wang Junzhi, from the Chinese Academy of Engineering and also deputy head of an expert task force on vaccine development under the State Council, made the remarks at a briefing in Wuhan.

“Regarding the development of Covid-19 vaccines, there will be a MAJOR NEWS ANNOUNCEMENT IN THE COMING ONE TO TWO WEEKS. IT’S AT THE FINAL STAGE NOW,” Wang said.

Two inactivated vaccines developed by China National Biotec Group (CNBG) and a third by Sinovac Biotech are in the final stage of clinical trials in South America, the Middle East and Asia but the drug makers have yet to release any of the phase 3 data needed for regulatory approval.

China tells recovered Covid-19 patients to wait six months before giving blood
CNBG data could be released “soon”, its parent company China National Pharmaceutical Group said on Saturday, while Sinovac is also expected to make an announcement on its phase 3 trial imminently. A Sinovac spokesman said the company could not provide further details when reached for comment on Friday.

Wang’s disclosure comes after Vice-Premier Sun Chunlan, who is in charge of public health in China, visited a company under CNBG, as well as Sinovac and the national agency that oversees vaccines in Beijing on Wednesday. She told the drug makers they should “be prepared for large-scale production” of vaccines.

https://malaysia.news.yahoo.com/coronavirus-china-600-million-doses-080907555.html

Stock

Stock: [BINTAI]: BINTAI KINDEN CORPORATION BHD

2020-12-04 21:32 | Report Abuse

wow

Stock

Stock: [KANGER]: KANGER INTERNATIONAL BERHAD

2020-12-04 15:10 | Report Abuse

0.18 is highly unlikely. Most likely 0.175...

Welcome! Select a username of your choice.

NPRA1985

Summary

User Comments

Report Abuse